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ABSTRACT 
Intraocular pressure (IOP) is an important physiologic characteristic in 
maintaining the structure and function of the eye. Elevated IOP is a major risk factor of 
primary-open angle glaucoma and the only target for current glaucoma therapy. The goal 
of this study is to identify rare and low frequency variants in regulation of IOP. 
Using the exome array data, we performed a genome-wide association study for 
IOP in 1,661 unrelated individuals from a population-based cohort, the Beaver Dam Eye 
Study (BDES). IOP was adjusted for age, sex, systolic blood pressure, IOP treatment and 
population stratification. We conducted single-variant analysis on 35,091 low frequency 
and common variants and gene-based analysis on 9,650 gene regions with at least two 
protein-altering variants.  
IOP was significantly associated with rs52809447, located in GGA3 at 17q25 
(MAF=1.11%, p = 1.3 ! 10-6) and with rs757702, located in OGDH at 7p14-p13 (MAF = 
1.60%, p = 1.5 ! 10-6). Two novel loci, the HAP1 (huntingtin-associated protein 1) at 
17q21 (p = 1.1 ! 10-6) and TNR (tenascin R) at 1q24 (p = 3.0 ! 10-6) reached genome-
wide significance in gene-based analysis. The inhibitory role of TNR gene in retinal 
ganglion cell survival and axonal regeneration suggests a potential involvement in the 
glaucomatous progression. The implications of GGA3, OGDH and HAP1 with 
Alzheimer’s disease and IOP, lend support to the shared pathways of neurodegeneration 
in the brain and in the eye. 
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Glaucoma is a leading cause of visual impairment and irreversible blindness 
globally 1. As the population ages, the number of people with glaucoma is increasing 
rapidly. It is estimated that by the year of 2020, there will be around 80 million people 
with glaucoma worldwide 1. Primary open-angle glaucoma (POAG) is the most common 
form of glaucoma, accounting for over 70% of all glaucoma cases 2. Except for juvenile-
onset POAG, which follows a Mendelian inheritance, adult-onset POAG is considered a 
complex trait with a multifactorial etiology involves both genetic and environmental risk 
factors.  
Intraocular pressure (IOP) is an important physiologic characteristic in 
maintaining the structure and function of the eye 3. As one of the three ophthalmologic 
vital signs, the level of IOP provides essential information in the evaluation of ocular 
health. Normal IOP is regulated by the balance between the production and the drainage 
of aqueous humor through the trabecular meshwork in the anterior chamber angle of 
human eyes. Clinically, IOP ranging from 10 mmHg and 21 mmHg is considered normal 
4. 
Elevated IOP is a major risk factor of glaucomatous optic neuropathy, and the 
only target for current glaucoma therapy. A one mmHg increase in baseline IOP above 
the population average was associated with 10-14% greater risk of developing POAG in 
the following 5-9 years 5,6,7. Results from clinical trails have repeatedly showed that IOP 
lowering treatments in eyes with ocular hypertension are effective both in preventing the 
glaucoma onset and delaying its progression, and that eyes with normal tension glaucoma 
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also suffer less progression of field loss 8,9. Elevated IOP contributes to the accelerated 
death of retinal ganglion cells (RGCs) and the damage of the optic nerve, and ultimately 
results in progressive visual filed loss and eventually blindness in glaucoma patients 10. 
Genetic Components for IOP and POAG 
Intraocular pressure is a heritable polygenetic trait with environmental influences 
11. Heritability for IOP is consistently estimated in the range of 0.30 – 0.42 in population-
based studies of European ancestry 11,12,13. Based on the familial correlations in the 
Beaver Dam Eye Study (BDES) population, Duggal et al. 11 and Klein et al. 13 previously 
reported 30% - 36% of the total variation of IOP explained by the additive genetic effects. 
Family-based linkage studies in populations of European ancestry have located 
two regions on chromosome 10q22 14 and chromosome 19p 15 with significant linkage to 
IOP. Other linkage studies across different ethnicity groups also reported a number of 
suggestive linkage regions on chromosome 5, 6, 12, 13, and 14, including a region that 
harbored WDR36, a susceptibility locus for POAG 16,17,18. However, no causal gene in 
these regions has yet been identified for IOP. 
Genome-wide association studies (GWAS) have revealed evidence of multiple 
loci associated with IOP. Novel associations in GAS7 region on chromosome 17p13 and 
TMCO1 region on chromosome 1q24 were first discovered in a large GWAS from 
Netherlands 19, and both associations were replicated in a meta-analysis of three US 
population-based cohorts20.  The associations for IOP in TMCO1 region overlap with 
those for advanced POAG 21, suggesting that loci in this region can produce IOP changes 
that lead to glaucomatous optic neuropathy later in life. Other significant genetic 
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associations with IOP include the GLCCI1/ICA1 region on 7p21 22, and the MVB12B 
region on 9q33 23. However, neither of these recently identified loci has been replicated. 
GWAS have yielded a number of loci associated with POAG. Significant 
association of common variants between CAV1 and CAV2 genes on chromosome 7q31 
were discovered 24 and replicated in independent populations of European descent 25. 
Four GWAS across different ethnicity groups each reported significant associations 
between POAG and the CDKN2BAS region on 9p21 26,27,28,29, and two of the GWAS 
identified the SIX1/SIX6 region on 14q23 as a susceptibility locus for POAG 26,29. 
Study Objectives 
Genomics studies of IOP may elucidate key biological pathways and improve our 
understanding of the pathogenesis of disease.  
Traditional genetic approaches including family based linkage analysis and 
genome wide association studies may localize a gene region or gene, but do not have the 
resolution to identify causal alleles. Next generation sequencing provides an opportunity 
to investigate associations with rare and low frequency variants but can be costly for 
large studies. The exome array is a cost-effective option for the identification of rare and 
low frequency variants that may contribute to complex diseases.  
The primary goal of this study is to identify novel variants associated with IOP 
and to replicate previously reported genetic variants in the following gene regions 





Genome-wide association studies have identified hundreds of genetic variants that 
are reproducibly associated with complex human diseases and traits, and have provided 
valuable insights into the complexities of their genetic architecture. Although a 
substantial proportion of individual differences in disease susceptibility is known due to 
genetic factors, most common variants identified confer relatively small increments in 
risk, and explain only a small portion of overall heritability 30. Both evolutionary studies 
and empirical data suggest that for complex disease, extreme allelic heterogeneity is 
caused collectively by multiple rare and low frequency variants with moderate to high 
penetrances 31, thus highlighting the importance of identifying less common variants. 
While in principle sequencing studies can reveal the role of rare and common variants in 
complex diseases and traits, there are analytic challenges. Table 1 outlines the features 
and limitations of statistical approaches in detection of rare variant associations. 
Single-Variant and Multiple-Variant Approach 
The conventional single-variant approach assesses individual variants for 
association with a disease or trait, by performing a standard univariate statistical test, 
such as Pearson "2 test, Fisher’s exact test, Cochran-Armitage test for trend, or a 
likelihood ratio test (LRT) for regression analysis. When applied to rare variants, the 
power of the single-variant approach is limited due to the small number of observations 
 5 
for any given variant and a more stringent multiple-test corrections as compared to 
common variants 32,33. 
Given that many different mutations collectively contribute to a complex disease 
or trait, it may be beneficial to focus on the group rather than on each variant individually. 
An alternative to single-variant approach is to employ a multiple-variant analysis, which 
tests a number of variants in a defined functional unit (e.g. gene, pathway) 
simultaneously with the use of multivariate methods, such as Fisher’s product method, 
Hotelling’s T2 test, or LRT in linear/logistic regression 34. The multiple-variant approach 
usually involves a large number of degrees of freedom that results in substantial power 
reduction. As suggested by simulation data, the type I error rate of multiple-variant test is 
inflated when rare variants were analyzed in regression models 34. Although permutation 
can be used to control for type I error, its application in the whole genome scale can be 
computationally intensive. 
Collapsing/Sum Methods 
As an extension to the multiple-variant approach, burden tests assess the 
cumulative effects of multiple variants in a functional unit (e.g. gene, pathway) by 
collapsing or summarizing the rare variants within the region into a single variable, which 
is then tested for association with the disease or trait. 
There are various ways to aggregate the information of multiple loci within a 
region. In the cohort allelic sums test (CAST), the count of minor alleles is summed over 
all variant sites in a region for cases and controls, and a statistical test is applied to 
determine if the difference in these sums is greater than would be expected by chance 35. 
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A standard univariate test (e.g. Pearson’s "2 test or LRT in logistic regression) can then 
be applied to determine its statistical significance 34,36. 
Similar sum methods can be generalized to test quantitative trait associations 
where the phenotype is modeled in a linear regression framework as a function of either 
the direct count of minor alleles over all variant sites 33,37, or the proportion of variants 
sites that a minor allele presents 36. The genotype can also be represented in a 
dichotomous indicator variable taking the value 1 if a minor allele is present at any of the 
variant sites in a region, or 0 otherwise. For each of these three sum methods, the 
likelihood ratio test is constructed to make statistical inference of the cumulative 
association of rare variants with the quantitative trait. 
Independent simulation studies demonstrate that the collapsing/sum method 
performs considerably better than a single-variant and multiple-variant approach for 
qualitative traits across a variety of scenarios that differ in sample size, variant allele 
frequencies, proportion of causal variants in a region and total number of variants being 
collapsed 34,37. The results for quantitative traits are similar 36. Comparing the collapsing 
method based on dichotomous variable to the sum method on a count/proportion variable, 
studies found that the sum method always had equivalent or better power than the 
collapsing method across different scenarios 36,38. 
In general, burden tests based on collapsing/sum methods can enrich the 
association signal and at the same time reduce the number of test’s degrees of freedom, 
and hence improve its power for the detection of rare variants. However, this approach 
relies greatly on a key assumption that variants within the region have individual effects 
in the same direction and magnitude, and each contributes to the disease susceptibility 
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independently. In the presence of both protective and detrimental variants in the same 
region, the power of the burden test is diminished as these counteracted effects nullify the 
association signals. Moreover, misclassification of variants resulting in exclusion of 
causal variants and/or inclusion of non-causal variants could adversely affect the power 
34,37. 
CMC Method and Variable-Threshold Approach 
A number of strategies have been adopted to address the issue of misclassification. 
One common approach is to collapse/sum variants according to a minor allele frequency 
(MAF) threshold. It is suggested that the variants below the specified MAF threshold are 
more likely to be functional than the more common variants. Thus this approach is aimed 
to increase the proportion of causal variants being tested in each collapsed region.  
 In the Combined Multivariate and Collapsing (CMC) method, variants in a 
region are divided into subgroups on the basis of predefined criteria of MAF, and within 
each group variant are collapsed/summed. A multivariate test (e.g. Hotteling’s T2 test, 
LRT) is then applied for analysis of the groups of variants 33,34. Compared to the original 
collapsing/sum methods where all variants regardless of their functional consequence 
were aggregated into a single group, the CMC method is more robust to misclassification 
when non-causal variants are grouped with causal variants 34,37.  
The application of the CMC method to an empirical sequencing data shows that 
optimal power of this method can only be achieved when true causal variants have an 
allele frequency consistent with the proposed threshold 33. However, different genes may 
have very different relationships between allele frequency and functional effect. This 
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motivates an extension of the CMC method to a variable-threshold approach that can 
adapt to properties of individual genes 33. Using this variable-threshold approach, rare 
variants in each region are grouped together by an optimized allele-frequency threshold 
that maximizes the test statistics in the data. An exact p value is then obtained from 
permutation to control for type I error 33. Although the variable-threshold approach 
performs well relative to original CMC method, the optimizing procedure and the 
required permutation make implementation of this approach challenging in genome-wide 
studies. 
Weighted Sum Test 
Another approach to minimize the power reduction due to misclassification is to 
incorporate weight that reflects the likelihood of a variant to be functional. Decreasing 
the weight of non-causal variants and increasing the weight of causal variants can 
improve the power of burden tests. In a case-control study, a weighted sum test collapses 
a set of variants into a single weighted average of the number of minor alleles. The 
weight for each variant is defined as a function of the expected variance of minor allele 
counts in the control population. Thus a mutation that is rare among unaffected 
individuals has a higher weight than one that is common among the unaffected 
individuals 37. The phenotype is permuted (e.g. affected/unaffected status) to control for 
type I error 33,37. Similar weight schemes can be applied to the burden test for quantitative 
traits, in which case the statistical significance can be assessed via a Monte Carlo p value 
32. 
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In addition to weighting variants as a function of allele frequency, incorporating 
computational predictions of the functional consequence for rare variants (e.g. PolyPhen-
2 score) can also boost the power of the original burden test in which rare variants are 
weighted equally 33.  
Several independent simulation and empirical data analyses conclude that the 
weighted sum method has the best power when all variants in the targeted region affect 
the phenotype in the same direction 38,39. Both the CMC method and the weighted sum 
method, are more robust relative to other burden tests in the presence of misclassification, 
33,34,37,39. However, all forms of burden tests in general are subjected to the power 
reduction due to presence of variants with opposite effects in the same region. 
C-alpha Test 
In contrast to burden tests that seek to determine if the mean of allele count is 
biased from what is expected under the null hypothesis, the C-alpha test is based on the 
variance of allele counts to determine whether alleles are randomly distributed across 
cases and controls as expected under the null hypothesis of no association, or follow a 
mix distribution as a result of detrimental, neutral and protective variants presenting at 
the same region 38. From the simulation results, C-alpha shows comparable or slightly 
better power than burden tests when the effects of rare alleles are uniformly in one 
direction and much greater power when protective and detrimental variants are mixed 38.  
The C-alpha test is robust to the direction and magnitude of effect. However, as 
with other burden-style tests, C-alpha requires permutation for accurate significance 
estimation, especially when the number of variants in the region is small or when variants 
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are strongly correlated 38. Furthermore, the C-alpha test requires comparisons between 
two populations (i.e. cases versus controls) and thus has very limited application to 
analyze quantitative traits 32. 
SKAT and Optimal SKAT 
The sequence kernel association test (SKAT) is proposed to overcome the 
limitations of burden test and C-alpha test. SKAT uses a multiple regression model as in 
the multiple-variant approach to directly regress the qualitative or quantitative phenotype 
on genetic variants in a region. Since no collapsing/summarizing is required, SKAT 
allows different variants to have different direction and magnitude of effects, including 
no effects. The regression framework of SKAT accommodates for easy adjustment of 
covariates, such as principal components, to account for population stratification 32.  
Due to the large number of degrees of freedom, the likelihood ratio test has 
limited power, particularly for rare variants. Therefore, SKAT compares the extended 
model including the variant effects to the null model of covariates alone, and uses a 
variance-component score test to examine whether the coefficient for each variant in the 
region follows a distribution under the null hypothesis of no association 32.  
The correct weighting scheme can improve the power of SKAT. The default 
weight in SKAT is calculated from a beta distribution density function with pre-specified 
shape parameters evaluated at the sample MAF ( !! ! !"#$!!!"#!!!! ! !!!! ! !"!!. 
In practice, this weighting scheme increases the weight for rare variants while putting 
sufficient weights for variants with MAF 1%-5%. Under the null hypothesis, the 
variance-component score statistic follows a mixture of chi-square distributions. A 
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computationally efficient algorithm is used to approximate this mixed distribution and 
estimate the p value for significance 40. 
SKAT has improved power over burden tests in the presence of causal variants 
with opposite effects, and is generally the most powerful method across all scenarios with 
one exception. SKAT assumes that variants act independently to affect disease risk. 
Without accounting for correlations between variants, SKAT is less powerful than burden 
tests when a large number of variants in a region are causal and in the same direction. 
Since in practice the correlation between variants is unknown and can vary from one 
region to another across the genome, a data-adaptive optimal test (SKAT-O) 
incorporating the correlation parameter was developed. SKAT-O consists of a class of 
tests including burden test and SKAT as special cases, and derives an optimal test within 
the class that maximize the power 41.  
A simulation study in SKAT-O suggests that when the sample size is moderate or 
large (i.e. 2000 or 5000), type I error is accurately controlled at moderate # levels, but is 
slightly inflated at very stringent # levels (i.e. 2 ! 10-6). If the sample sizes are small, the 
precise control of type I error is necessary. Permutation-based procedures can be used to 
generate a Monte Carlo p values for significance, though this can be computationally 
expensive.  
SKAT-O has comparable power to burden tests in the presence of a large 
proportion of causal variants and is most powerful when the proportion of causal variants 
is low. Meanwhile, both SKAT and SKAT-O outperform burden tests when the causal 
variant coefficients are in mixed directions 41.  
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In conclusion, SKAT-O is a computationally efficient regression approach that 
allows flexible adjustment for covariates. Comparing to burden tests, SKAT-O performs 
very well under broader circumstances. Although SKAT and SKAT-O are more robust to 
misclassification, they still suffer a substantial power reduction as the number of non-
causal variants included in the model increases. Prior knowledge in the functional 
consequences of rare variants can be utilized to guide the variant selection to optimize the 
power of SKAT analysis. 
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MATERIALS AND METHODS 
Study Population 
The Beaver Dam Eye Study (BDES) is a population-based cohort study 
established in Beaver Dam, Wisconsin in 1987 42. At the time the BDES was initiated, 
Beaver Dam, Wisconsin was a well-defined community with a primarily white 
population of approximately 17,000 individuals. From 1987 to 1988, the Wisconsin 
Survey Research Laboratory conducted a complete census of the city and township of 
Beaver Dam and identified 3,715 households with at least one occupant aged from 43 to 
84 years. Individuals in the targeted age range were contacted by telephone and invited to 
participate in the examination phase of the study. Of the 5,924 individuals eligible to 
enroll, 4,926 (83.14%) individuals underwent a complete ocular examination and a 
personal history questionnaire during 1988 - 1990. For the 2,336 participants with known 
familial relationships in the catchment area of the study, pedigrees were constructed and 
the familial relationships were confirmed at their five-year follow-up visits.  
We selected individuals from the parent BDES cohort with extreme baseline IOP 
or refractive error measurements with available covariate information. The informed 
consent was obtained from all study participants and the institutional review board at the 
University of Wisconsin approved all protocols. The Johns Hopkins University 
institutional review board also approved the statistical analysis of these existing data. 
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Clinical Evaluation 
Detailed medical histories and eye examinations were performed for each 
participant at the baseline evaluation 11. To maintain consistency and validity of 
measurements, all examinations were carried out by trained observers. IOP was measured 
with a Goldmann applanation tonometer after instilling a drop of fluorescein combined 
with a topical anesthetic (Fluoress; Barnes-Hind Armour Pharmaceutical Co., Kankakee, 
IL) in each eye. Before measuring the IOP in one eye, the tonometer was set to 10 mm 
Hg and the pressure was recorded only after the tonometer was moved back from the 
cornea. The procedure was repeated for the other eye. Any unreliable measurement 
marked by the observers was excluded from the analysis. Blood pressure was measured 
according to the Hypertension Detection and Follow-up Program (HDFP) protocol. A 
detailed medical history, including information about hypertension, diabetes, and other 
medical conditions and history of medication use, was obtained from each participant. 
Although longitudinal eye measurements were collected, only baseline examination of 
IOP measurements was used in this analysis.  
DNA Extraction and Genotyping 
For 66% of participants, DNA was extracted from buffy coat separated at the time 
of the blood draw from the second or third Beaver Dam visit and stored at -80° C. For 
20% of participants, DNA was extracted from frozen whole blood cells from the first 
examination. The remaining 14% individuals had their DNA extracted from both sources. 
All participants were genotyped on Illumina HumanExome-12 V1-1 BeadChip at 
the Genetic Resources Core Facility (GRCF) at Johns Hopkins Institute of Genetic 
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Medicine. Genotyping calling was carried out using Illumina’s GenTrain version 1.0 
clustering algorithm in GenomeStudio version 2011.1. 
The Illumina HumanExome-12 V1-1 BeadChip targets 242,901 variants, the 
majority of which are protein-altering variants (i.e. non-synonymous, splice and stop 
altering variants) selected from ~ 12,000 sequenced genomes representing multiple 
ethnicities and complex traits. The exome array also includes previously reported GWAS 
associations, ancestry informative markers (AIMs), HLA tags, randomly selected 
synonymous variants and variants for identity-by-descent (IBD) estimation. Details about 
exome array content and selection strategies can be found at the exome array design 
webpage (http://genome.sph.umich.edu/wiki/Exome_Chip_Design). 
Quality Control Procedures 
We applied both sample-level and marker-level quality control filters. Figure 1 
illustrates the quality control procedures for our exome array data. 
Quality Control for Samples 
In total, 1,973 of 2,098 (94.0%) attempted samples were successfully genotyped 
and passed quality control metrics (i.e. GenCall score > 0.15 and call rate > 98%). We 
identified 36 sex discrepancies of which 21 had a sex chromosome abnormality. The 
remaining 15 individuals were excluded from further analysis. Since this is a population-
based study that included families, we evaluated cryptic relatedness. Using pairwise IBD 
sharing and 4,801 common variants across the autosomes we identified 156 close 
relatives with IBD sharing > 0.20 (Figure 2). Based on the pedigree data, we further 
confirmed the relationships of these 156 individual pairs as15 parent-child pairs, 50 full-
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sibling pairs, 6 first-cousin pairs, 73 avuncular/grandparent-child pairs and 12 unexpected 
duplicate pairs. In addition, the estimated genome-wide IBD sharing identified a parent-
child pair with a Mendelian inconsistency. Thus, we excluded 127 samples with the 
lower sample call rate from the confirmed relative pairs with cryptic relatedness or 
Mendelian error. 
All BDES participants had baseline IOP measurements in both eyes. Potential 
confounding variables were included as covariates in the analyses including age, sex, 
systolic blood pressure, and IOP treatment. 105 samples were missing one or more of 
these values for the specified covariates and were excluded, leaving 1,661 individuals for 
the association analysis (Figure 1).  
Quality Control for Markers 
In total, 236,546 of 242,901 (97.4%) attempted variants were successfully 
genotyped and had call rate > 95%. The HapMap concordance rate was 99.82% and the 
genotype concordance among 21 blind duplicate sample pairs was 99.99%. We further 
restricted the variants to those on autosomal chromosomes with a call rate > 98%. A total 
of 158,595 variants were excluded because they were monomorphic (N = 132,202) or 
extremely rare with only one minor allele in the study sample (MAF<0.05%) (N = 
26,389), resulting in 75,669 variants for association analysis. Since departures from 
Hardy-Weinberg equilibrium (HWE) can be a result of evolutionary forces, genotyping 
errors, population admixture and marker-trait associations, we evaluated the HWE on the 
final set of variants, and reported the p value estimated from the HWE exact test for 
significant associations 43. 
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Assessment of Population Stratification 
The BDES population self-reports as primarily European-American. To evaluate 
the genetic ancestry we performed principal component analysis (PCA) using 
SMARTPCA in EIGENSTRAT 4.2 44. There are 2,736 ancestry informative makers 
(AIMs) designed to distinguish Native Americans and Africans from European ancestry 
in the genotyped array. Figure 3 shows the plot of PCA clusters for BDES samples and 
44 HapMap controls from seven ancestry groups, and there is no apparent population 
substructure in the study samples. The first two principle component scores from the 
PCA analysis were incorporated as covariates for IOP adjustment. 
Statistical Analysis 
Quantitative Trait Adjusted for Covariates 
For the quantitative trait analysis, the higher baseline IOP measurement from 
either eye was used. The distribution of intraocular pressure was approximately normal. 
(Figure 4). Prior to the association analysis, the trait was first adjusted using a linear 
regression model as a function of age, sex, systolic blood pressure, IOP treatment, and the 
first two principal components. Then for each participant, the variation of IOP due to the 
individual’s specific values of covariates was calculated and subtracted from the 
observed IOP measurements to generate an adjusted IOP value. The adjusted IOP values 
were used in the association analysis. 
Annotations 
Annotation was performed using SeattleSeq Annotation Server 138 version 9.01 
under CRCh37/hg19 (see URLs). Except for 57 insertions and deletions, nearly all 
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variants (N = 75,612) that passed quality control filters were annotated. This server 
recognizes each variant by its CRCh37/hg19 position, and returns a variety of annotations 
derived from the Genome Variation Server (GVS) database, which integrates information 
from dbSNP, UCSC, NCBI and several other sources.  
Single-Variant Analysis 
Single-variant analysis was conducted to test the association of individual variants 
with IOP assuming additive effects. The analysis was performed using linear regression 
models for quantitative trait implemented in PLINK’s ‘--assoc’ option, which estimates 
the significant values from the Wald test assuming a normal distribution of the trait 45. 
We restricted this analysis to low frequency and common variants with MAF $ 1% (N = 
35,091), corresponding to approximately 30 copies of the minor allele in the analyzed 
cohort. Given the sample size of the study, the lower limit of 1% MAF allows stable 
estimates of sampling errors and provides adequate statistical power to detect low 
frequency variants with effect size (%) greater than 2.5. We set the genome-wide 
significance threshold to p < 1.5!10-6, corresponding to a Bonferroni correction for 
35,091 tests.  
Permutation tests were performed for variants with significant associations. The 
empirical p-values for these variants were obtained via 10,000,000 permutations using 
PLINK’s ‘--mperm’ option, applying a label-swapping approach. This option assumes 
carriers and non-carriers of a given variant are interchangeable under the null hypothesis 




We performed gene-based analysis using SKAT-O implemented in R 46, 47. The 
adjusted IOP was regressed on rare and low frequency variants (MAF 0.05% - 5%) in a 
gene region, allowing them to have different directions and magnitude of effects. Both 
simulation studies and real data analysis suggest that SKAT-O suffers a considerable 
power reduction when a large proportion of non-causal variants in the region are included 
in the analysis. Therefore, we limited the gene-based analysis to protein-altering variants, 
as they are more likely to result in functional alternations. A total of 58,043 variants were 
annotated to have a missense, nonsense, splice site, or frameshift consequence. We 
grouped these variants into their gene regions and allowed them to be analyzed in 
multiple regions if they were located in overlapping genes.  
To maximize the statistical power, we applied the default weight !! !
!"#$ !"#!!!! ! !!!! ! !" , which up-weights rarer variants while still putting 
nonzero weight for low frequency variants. After limiting the SKAT-O analysis to gene 
regions with at least two variants meeting the pre-specified criteria, we tested 9,650 genes 
consisting of 45,867 variants across autosomal chromosomes. For each gene region, the 
statistical significance of the variance-component score statistic was estimated from a 
mixed "2 distribution under null hypothesis of no association 41. The genome-wide 
significance threshold was set to p < 5.2 !10-6, corresponding to a Bonferroni correction 
for 9,650 tests. To ensure the accurate inference, we filtered the gene-based results with a 
cumulative MAF < 1% for SKAT-O analysis, corresponding to approximately 30 copies 
of the minor allele across the analyzed cohort. 
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Replication of Published GWAS Loci 
To replicate the association of published GWAS loci, we manually identified 30 
variants in or near the reported CAV1/CAV2, CDKN2BAS, SIX1/SIX6, TMCO1, GAS7 
and GLCCI1/ICA1 regions. Given that some of these loci were originally identified for 
POAG, we examined their single variant associations on IOP with and without 
adjustment for the glaucoma status in the model. Empirical p values were obtained for 
these variants via 10,000 permutations. Associations of these variants were considered as 





The characteristics of the 1,661 Beaver Dam Eye Study participants are 
summarized in Table 2. Females constitute 59.8% of the analyzed cohort and the mean 
age was 60 years for both men and women. The distribution of IOP in our study sample 
had a mean 15.6 mmHg with standard deviation 4.1 mmHg, which is comparable to other 
large population-based cohorts of European descent. The mean IOP of similar aging 
populations in the Blue Mountain Eye Study (BMES) and the NEIGHBOR consortium 
was 16 mmHg  48 and 15.4 mm Hg 49, respectively. The mean and median of IOP 
measurements in this study (15.0 mm Hg vs. 15.6 mm Hg) were very close, supporting a 
normal distribution for this quantitative trait. Nine-percent of the individuals had elevated 
IOP defined as > 21 mm Hg, and about three-percent of the analyzed cohort had reported 
IOP medical treatment. The mean systolic blood pressure was 130 mm Hg and the mean 
diastolic blood pressure was 77 mm Hg. The IOP values after adjusting for age, sex, 
systolic blood pressure, treatment for IOP and the first two principal components follows 
an approximately normal distribution with mean of 10.3 mm Hg and standard deviation 
of 3.8 mmHg (Figure 4). 
Single-Variant Associations 
A total of 35,091 low frequency and common variants (MAF $ 1%) were tested 
individually for association with IOP. We identified two novel associations at GGA3 and 
OGDH (Figure 5,Figure 6).  
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GGA3 Loci 
The most significant association with IOP was a missense variant on chromosome 
17 (rs52809447, nominal p = 1.3 ! 10-6, empirical p = 3.7 ! 10-5) in the exonic region of 
the golgi-associated gamma adaptin ear containing ARF binding protein 3 (GGA3) gene. 
Each copy of minor allele C of variant rs52809447 results in a 3.05 mm Hg increase in 
IOP (95% CI = [1.77,4.33]). The A to G polymorphism substitutes a glutamic acid 
residue with a glycine residue at amino acid 97 (c.290A>G, [p.Glu97Gly]). 
The products of GGA family include the ubiquitous coat proteins that regulate the 
trafficking of proteins between the trans-Golgi network and the lysosome. This gene 
family plays a significant role in Alzheimer’ disease (AD) pathogenesis where GGA3 
acts as a central regulator of %-Site APP-cleaving enzyme (BACE1) trafficking and 
degradation. The cerebral accumulation of amyloid-beta (A%) protein is a key neuro-
pathological event in AD and the BACE1 cleaves the amyloid precursor protein (APP) at 
the %-secretase site to initiate the production of A% peptides 50. Depletion of GGA3 
during apoptosis stabilizes BACE1 by impairing its sorting to lysosome where it is 
normally degraded, and hence increases the levels of A% protein in animal models 51. The 
inverse correlation between GGA3 and BACE1 protein levels in AD and ischemic brain 
samples suggest that GGA3 is responsible for enhanced BACE1 levels and A% 
accumulations during ischemia and in AD brain 51,52. 
Although there is no direct implication of GGA3 on IOP, POAG or any ocular 
disorders, an increasing number of studies indicate a potential participation of amyloid 
beta peptide (A%) in the retinal ganglion cell (RGCs) death following a long-term 
exposure to elevated IOP. Comparing to normal rat and monkey eyes, the glaucomatous 
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eyes with chronic ocular hypertension had significantly higher concentration of amyloid 
precursor protein (APP) and A% peptides in the optic nerves and RGCs 53,54. As in 
Alzheimer’s disease, the increased level of APP and excess production of A% peptides in 
ocular hypertensive eyes were a result of the caspase activation, especially caspase-3 and 
caspase-8 55. Several studies have reported that inhibition of caspases enhances the 
survival of RGCs56,57. These molecule and mechanistic similarities suggest a potential 
involvement of GGA3 in the pathological event of RGCs death through interactions with 
caspases and APP, and provide evidence of common etiology between AD and glaucoma 
at the cellular level. 
OGDH Loci 
The second discovery was a novel association of a low frequency intronic variant 
(rs757702, MAF = 1.6%, nominal p = 1.5!10-6, empirical p = 3.4 ! 10-5) on chromosome 
7p14-p13 the 2-oxoglutarate dehydrogenase (OGDH) gene. One copy of the minor allele 
A of rs757702 was associated with 2.50 mm Hg increase in IOP (95% CI = [1.46, 3.54]).  
2-Oxoglutarate dehydrogenase (OGDH), also designated as #-ketoglutarate 
dehydrogenase (!-KGDH or E1k), encodes one subunit of the mitochondrial 2-
oxoglutarate dehydrogenase complex (OGDHC or KGDHC). OGDHC is a key 
regulatory enzyme in the tricarboxylic acid cycle (TCA cycle), participating directly in 
the bioenergetics processes58. OGDHC also plays an essential role in the degradation of 
glucose and glutamate, the excess of which are neurotoxic and have specific significance 
in the brain 59. Diminished OGDHC activity may predispose to oxidative stress and 
disturb the brain mitochondrial function through impaired energy production and glucose 
metabolism, which ultimately leads to the neurodegeneration in age-related disorders like 
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Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease 59. Animal studies 
also corroborate that deficits in glucose and oxidative metabolism were not the result of 
neurodegeneration but the early events that precede the overexpression of APP and the 
formations of A% plague in the neurodegeneration process 59. 
Interestingly, many ophthalmologic disorders involved age-related 
neurodegeneration are increasingly recognized to have an origin of mitochondrial 
dysfunction 60. The impaired cerebral glucose utilization and deranged bioenergetics in 
AD were also observed in animal models of glaucoma 61,62. Elevated IOP induces the 
degenerative process of RGCs via mechanism of mitochondrial oxidation. Novel non-
synonymous mitochondrial DNA changes paralleled with reduction in respiratory 
activities in POAG patients indicate that oxidative stress and mitochondrial dysfunction 
may interactively contribute to the pathogenesis of POAG 63.  
A microarray analysis of retinal gene expression found differential regulation of 
OGDH gene over postnatal development period in mice 64. Although the role of OGDHC 
enzyme in the retina is unclear, the changes of its expression could potentially affect the 
metabolic rate of retinal cells, and through similar pathways as in the brain predispose 
risk of elevated IOP and glaucoma. 
Gene-Based Associations 
Gene-based test offers an alternative to single-variant analysis, which is often 
underpowered to detect associations with rare variants. In gene-based analyses, only 
protein-altering variants with rare and low minor allele frequencies (MAF 0.05% - 5%) 
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are included. We evaluated 9,650 genes having at least two such variants using the 
SKAT-O test.  
We filtered the gene-based results with a cumulative MAF < 1% and identified 
the HAP1 region on chromosome 17q21 and the TNR region on chromosome 1q24 to be 
significantly associated with IOP.  
HAP1 Region 
Novel association with huntingtin-associated protein 1 (HAP1) on chromosome 
17q21.2-q21.3 reached the genome-wide significance (CMAF = 2.05%, p = 1.13 ! 10-6). 
Four missense variants contributed to the gene-based analysis, including one low 
frequency variant rs34853043 that showed a suggestive association with IOP in single-
variant analysis (MAF = 1.11%, nominal p = 3.72 ! 10-5, empirical p = 2.1 ! 10-4).  
HAP1 encodes a protein interacting with huntingtin (Htt), the Huntington’s 
disease (HD) protein. HAP1 is expressed predominantly in the neurons of the brain. Htt 
and HAP1 both participate in intracellular trafficking and vesicular transport65. Together, 
they regulate the level of a polygutamine expaded Htt (polyQ-htt). Disruption of this 
regulation causes aggregation of polyQ-htt, which leads to the neurodegeneration and cell 
death in HD66. 
HAP1 may also participate in the pathophysiological change of the Alzheimer’s 
disease. In the neurodegenerative process, amyloid precursor protein (APP) is axonally 
transported, endocytosed and sorted to different cellular compartments to initiate the 
production of amyloid beta (A%). A study of the HAP1 protein knock-down mice with 
Alzheimer’s disease observed a decreased rate of APP transport and increased A% levels, 
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suggesting that HAP1 may control APP subcellular trafficking and negatively regulate 
A% in the neurons67. 
Given the implication of amyloid beta peptide (A%) in the apoptotic death of 
retinal ganglion cells, the regulatory role of HAP1 on APP and A% peptides in brain 
might be extended to a common pathway in the eye, contributing to the physiologic 
changes in glaucoma. 
TNR Region 
Tenascin R (TNR) on chromosome 1q24 (CMAF = 1.33%, p = 3.01 ! 10-6) was 
also significantly associate with higher IOP. Six rare missense variants in the TNR region 
contributed to the analysis.  
The TNR gene encodes a member of the tenascin family of extracellular matrix 
glycoproteins. The encoded protein is exclusively expressed in the central nervous system. 
It affects cell migration, adhesion and differentiation, although no remarkable clinical 
consequences have been shown in knock-out animal models 68. 
It is known that retinal ganglion cells (RGCs) death is a characteristic 
pathological event that precedes the glaucoma onset. Study of lesioned optic nerve of 
adult mice revealed that overexpression of tenascin-R was responsible for the failure of 
the regeneration of adult RGCs axons after injury69. The role of tenascin-R as a repellent 
guidance molecule for newly growing and regenerating axons has been observed for 
different neuronal cell types across different species in vitro 69,70. The inhibitory effect of 
TNR in retinal ganglion cells survival and axonal regeneration suggests a potential role in 
glaucomatous progression, particularly under stress of elevated IOP.  
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Replicated Associations of Published GWAS Loci 
Table 5 summarizes the coverage of each published GWAS loci for IOP and 
POAG in our exome array data. Except for MVB12B region, our exome array contains at 
least one variant for six published GWAS loci, among which the TMCO1, CAV1/CAV2, 
CDKN2B-AS1 and SIX1/SIX6 region have the same variants previously associated with 
IOP and/or POAG.  
Of the 30 variants in six GWAS loci, we successfully replicated the association of 
a previously published POAG variant rs4236601 on chromosome 7q31 that contains the 
caveolin genes CAV1 and CAV2 (Table 6). This association was first discovered with 
POAG in an Icelandic population (OR = 1.36 [1.23 – 1.50], p = 5.0 ! 10-10)24, and was 
later replicated in two independent studies in populations of European ancestry 25, 71. The 
detected association in our study (% = 0.46, nominal p = 1.9 ! 10-3, empirical p = 1.8 ! 
10-3) is consistent in direction with the POAG studies, namely, the minor allele A of 
variant rs4236601 was associated with elevated IOP and also higher risk of POAG 24. In 
all three POAG studies, cases were consisted of both normal-tension and high-tension 
POAG patients, suggesting that rs4236601 could increase the risk of POAG through 
affecting IOP levels. However, in one of the POAG studies, analysis on the subgroup of 
high-tension POAG individuals revealed no association with rs4236601 25. 
Our result is also in agreement with two meta-analyses of IOP in Caucasian 
populations (Koolwijk et al.19, % = 0.19, p = 1.1 ! 10-4; Ozel et al.20, % = 0.38, p = 2.8 ! 
10-4). The adjustment of glaucoma status in our analysis did not affect the association of 
rs4236601 with IOP (% = 0.46, nominal p = 2.0 ! 10-3, empirical p = 2.8 ! 10-3), which 
may be reflective of the small number of self-reported glaucoma cases. 
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The proteins encoded by caveolin-1 (CAV1) and caveolin-2 (CAV2) gene are both 
major components of the caveolar plasma membranes. Caveolin-1 is expressed in several 
retinal cell types, including photoreceptor, retinal vascular endothelia cells, Müller galia, 
and retinal pigment epithelium (RPE) cells. Recent evidence links caveolin-1 to ocular 
pathologies including autoimmune uveitis, diabetic retinopathy, and POAG, but its role in 
the retina is largely unknown. Genetic ablation of caveolin-1 causes retinal functional 
deficits due to disruptions in micro-environmental homeostasis72 and blood-retinal barrier 
(BRB) breakdown 73. A cytotoxic agent that increases intraocular pressure and aqueous 
outflow resistance in mice can also cause increased expression of caveolin-1 in the 
treated human trabecular meshwork cells 74. Further investigations are required to 
elucidate the role of caveolin-1 and caveolin-2 in controlling IOP. 
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DISCUSSION 
The contribution of rare and low frequency variants to complex diseases and traits 
has been long debated. In this study, we performed the first exome array analysis on 
1,661 BDES participants to identify rare and low frequency variants influencing 
intraocular pressure. We discovered two low-frequency variants with large effects on IOP 
in the single-variant analysis: variant rs52809447 (% = 3.05 mmHg, nominal p = 1.3 ! 10-
6) in the GGA3 region on chromosome 17 and variant rs757702 (%= 2.50 mmHg, nominal 
p = 1.5!10-6) in the OGDH region on chromosome 7. The gene-based analysis reported 
two genome-wide significant associations with IOP in the HAP1 region on chromosome 
17q21 and TNR region on chromosome 1q24, 
In our discussion of the biological plausibility and the potential contribution of 
these four identified regions for IOP, we noticed an interesting connection between three 
of the genes and the Alzheimer’s disease. Both GGA3 gene and HAP1 gene on 
chromosome 17 contribute to AD through indirect regulation of the A% peptide 
production, the excess of which is neurotoxic and has strong implication in both AD and 
glaucoma. The OGDH gene on chromosome 7 linked to AD through mechanisms 
involves interactions between mitochondrial dysfunction and oxidative stress, a 
mechanism that is also associated with a number of ocular disorders including elevated 
IOP and glaucoma. 
Glaucoma and Alzheimer’s disease are two chronic neurodegenerative diseases 
with a strong age-related incidence. Higher prevalence of glaucoma has been reported 
among AD patients in a number of population studies 75. Experimental studies in animal 
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models and human cell lines recognized several common pathogenetic pathways 
associated with both disorders, including mitochondrial dysfunction and A% peptide 
accumulation. These two mechanisms may act separately or synergistically in the 
pathogenesis of both glaucoma and AD. Although still not fully understood, research and 
clinical findings suggest a possible common causal relationship between AD and 
glaucoma. 
There are limitations to this study.  The Exome Array is constrained to the 
protein-altering variants including the non-synonymous coding and splice site variation 
observed in the ~ 12,000 individuals who comprised the initial exome sequencing 
discovery set. Thus majority of the exome array content have a low or rare minor allele 
frequency. In our analyzed cohort of 1,661 individuals, almost 70% of the variants in the 
genotyping assay are monomorphic or singletons. To detect the burden of such vary rare 
mutations to elevated IOP will require an extraordinarily large sample size. 
Gene-based analysis was performed on the regions with at least two variants in 
the targeted MAF range. After excluding gene regions containing only one variant, on 
average, each analyzed region had six variants contributing to the gene-based analysis. 
About 75% of these regions had no more than seven variants. In some cases, theses 
variants span across the entire gene region but in others they cluster at a relatively small 
range. This raises a concern of adequate coverage of gene regions with such a small 
number of variants.  
In addition, for a gene region with a small number of variants, the test is more 
likely to be driven by a single more common variant. This relatively common variant can 
be truly causal but when it is observed in only a handful of individuals, SKAT is less 
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competent to provide accurate significance estimations for the gene region. Therefore, we 
filtered our gene-based associations to two regions, as the variants contributing to the 
significant associations in both HAP1 and TNR region had cumulative MAF > 1%. To 
detect the associations in other gene regions, a larger sample size is necessary. 
In summary, we identified two low frequency variants in novel genetic loci and 
two new genes with rare and low frequency coding variants associated with intraocular 
pressure. The novel associations of three AD related genes, GGA3, OGDH and HAP1, 
lend support to the shared pathways of neurodegeneration in Alzheimer’s disease and 
glaucoma. The inhibitory role of TNR gene in retinal ganglion cell survival and axonal 
regeneration has a potential implication in the glaucomatous progression induced by high 
intraocular pressure. Given the limited coverage of exome array data for many rare 
variants, a larger sample size is needed for comprehensive assessment of the variants 
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